Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease

X
Trial Profile

Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melatonin/tetrahydrocannabinol (Primary)
  • Indications Alzheimer's disease; Anxiety; Dementia
  • Focus Therapeutic Use
  • Sponsors India Globalization Capital
  • Most Recent Events

    • 28 May 2024 According to an India Globalization Capital media release, the company has initiated patient enrollment at Neurostudies, Inc. in Port Charlotte, Florida. Neurostudies is led by Principal Investigator Dr. Liliana Montoya and Sub-Investigator Dr. George Li. IGC Pharma has 11 additional trial sites under contract and is on target to start additional sites in the U.S. and Canada.
    • 14 Aug 2023 According to an India Globalization Capital media release, On June 30, 2023, company entered into a stock purchase agreement with several investors for $3 million in gross proceeds further strengthening working capital and supporting the advancement of Phase 2 studies for IGC-AD1 in Alzheimers disease. This amount is not reflected on the balance sheet as of June 30, 2023, as the proceeds were received after the close of the quarter.
    • 06 Jul 2023 According to an IGC Pharma media release, the company announces a 3 million USD private placement of its common stock. The funds support the advancement of the Companys Phase-2 clinical trial of IGC-AD1, the Companys promising investigational drug candidate designed to address agitation in dementia caused by Alzheimers disease.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top